MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 522412 | Name: BMY-42393

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. BMY 42393 competed for radiolabeled iloprost and PGE1 binding to platelet membranes (IC50; 170 nM and 130 nM, respectively).

Chemical Structure

BMY-42393
CAS#136451-58-6

Theoretical Analysis

MedKoo Cat#: 522412

Name: BMY-42393

CAS#: 136451-58-6

Chemical Formula: C26H18N2O5

Exact Mass: 438.1216

Molecular Weight: 438.44

Elemental Analysis: C, 71.23; H, 4.14; N, 6.39; O, 18.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMY-42393; BMY 42393; BMY42393.
IUPAC/Chemical Name
2-(3-(4,5-diphenyl-[2,4'-bioxazol]-5'-yl)phenoxy)acetic acid
InChi Key
DSRSEEYZGWTODH-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H18N2O5/c29-21(30)15-31-20-13-7-12-19(14-20)24-23(27-16-32-24)26-28-22(17-8-3-1-4-9-17)25(33-26)18-10-5-2-6-11-18/h1-14,16H,15H2,(H,29,30)
SMILES Code
O=C(O)COC1=CC=CC(C2=C(C3=NC(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)N=CO2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 438.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chow KB, Wong YH, Wise H. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. Br J Pharmacol. 2001 Dec;134(7):1375-84. PubMed PMID: 11724742; PubMed Central PMCID: PMC1573079. 2: Kam Y, Chow KB, Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Signal. 2001 Nov;13(11):841-7. PubMed PMID: 11583920. 3: Rudd JA, Qian Ym, Tsui KK, Jones RL. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br J Pharmacol. 2000 Feb;129(4):782-90. PubMed PMID: 10683203; PubMed Central PMCID: PMC1571884. 4: Jones RL, Qian YM, Wise H, Wong HN, Lam WL, Chan HW, Yim AP, Ho JK. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35. PubMed PMID: 9156364. 5: Wise H, Chow KB. The effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells. Adv Exp Med Biol. 1997;433:197-200. PubMed PMID: 9561134. 6: Wise H. The effect of prostacyclin mimetics on neutrophil function. Adv Exp Med Biol. 1997;407:261-4. PubMed PMID: 9321962. 7: Seiler SM, Brassard CL, Federici ME, Romine J, Meanwell NA. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins. 1997 Jan;53(1):21-35. PubMed PMID: 9068064. 8: Wise H. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Prostaglandins Leukot Essent Fatty Acids. 1996 May;54(5):351-60. PubMed PMID: 8832764. 9: Wise H, Qian YM, Jones RL. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors. Eur J Pharmacol. 1995 May 24;278(3):265-9. PubMed PMID: 7589166. 10: Seiler SM, Buchanan JO, Schumacher WA, Zavoico GB, Gamberdella M, Fleming JS, Meanwell NA. 2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): 2). Oral activity and efficacy in animal models of arterial thrombosis. Thromb Res. 1994 Apr 15;74(2):125-33. PubMed PMID: 8029813. 11: Seiler SM, Brassard CL, Federici ME, Buchanan JO, Zavoico GB, Fleming JS, Meanwell NA. 2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action. Thromb Res. 1994 Apr 15;74(2):115-23. PubMed PMID: 8029812. 12: Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, et al. Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring. Drug Des Discov. 1994 Jan;11(1):73-89. PubMed PMID: 7520762. 13: Kowala MC, Mazzucco CE, Hartl KS, Seiler SM, Warr GA, Abid S, Grove RI. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. Arterioscler Thromb. 1993 Mar;13(3):435-44. PubMed PMID: 8443148. 14: Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Zavoico GB, et al. Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. J Med Chem. 1992 Sep 18;35(19):3483-97. PubMed PMID: 1404230.

View History

ADB-5'Br-BUTINACA-d9

ADB-5'Br-BUTINACA-d9

Featured